Tempus AI, Inc. (NasdaqGS: TEM)
Health Care · Life Sciences Tools & Services · US
$67.20
+1.56% today · -12.8% 1Y
Tempus AI, Inc. (NasdaqGS: TEM) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $11.94B and employs 3,800 people.
Over the last twelve months the share price has lost 12.8%, trading between 40.77 and 104.32.
Tweenvest scores Tempus AI, Inc. across four factors: quality 26/100, value 73/100, growth 100/100. Its strongest factor is growth.
TEM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.94B
- Revenue (TTM)
- $1.43B
- P/E
- —
- EPS
- -1.43
- Dividend yield
- —
- Beta (5Y)
- 3.58
- 52-week high
- $104.32
- 52-week low
- $40.77
- Avg volume (3M)
- —
- Shares outstanding
- 180.43M
- Employees
- 3,800
- Next earnings
- —
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- ISIN
- US88023B1035
- Founded
- 2015
- Listed since
- Jun 14, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.47B | $631.29 | +0.41% |
| Danaher CorporationNYSE: DHR | $151.22B | $215.11 | -1.71% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $69.06B | CN¥155.84 | -4.31% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.21B | CHF593.40 | +0.95% |
| Agilent Technologies, Inc.NYSE: A | $43.33B | $153.43 | -3.50% |
| IQVIA Holdings Inc.NYSE: IQV | $42.84B | $260.24 | +0.16% |
| Waters CorporationNYSE: WAT | $40.36B | $410.75 | +0.01% |
Figures last refreshed Aug 18, 2026.